Kura Oncology (KURA) Accumulated Depreciation & Amortization (2014 - 2026)

Kura Oncology (KURA) has 12 years of Accumulated Depreciation & Amortization data on file, last reported at $3.2 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization fell 7.82% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 7.82% YoY) and the FY2025 annual result came in at $2.9 million, down 11.45% from the prior year.
• Accumulated Depreciation & Amortization climbed to $3.2 million in Q1 2026 per KURA's latest filing, from $2.9 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $3.9 million in Q3 2025 and bottomed at $1.0 million in Q1 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $2.7 million (2024), against an average of $2.5 million.
• The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization surged 159.14%; it then slipped 11.45% in 2025.
• Tracing KURA's Accumulated Depreciation & Amortization over 5 years: stood at $1.6 million in 2022, then soared by 52.96% to $2.5 million in 2023, then soared by 33.56% to $3.3 million in 2024, then retreated by 11.45% to $2.9 million in 2025, then advanced by 11.76% to $3.2 million in 2026.
• Per Business Quant, the three latest KURA Accumulated Depreciation & Amortization figures stand at $3.2 million (Q1 2026), $2.9 million (Q4 2025), and $3.9 million (Q3 2025).

Peer Comparison